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ABBR EV I A T I ON S
AND ACRONYMS
Ad DMEM = advanced
Dulbecco’s modified Eagle’s
medium
apoB = apolipoprotein B
CAD = coronary artery disease
CAVS = calcific aortic valve
stenosis
HDL-C = high-density
lipoprotein cholesterol
IQR = interquartile range
LDL-C = low-density
lipoprotein cholesterol
Lp(a) = lipoprotein(a)
PBS = phosphate-buffered
saline
PBST = 13 phosphate-buffered
saline with 0.1% Triton
PCSK9 = proprotein
convertase subtilisin/kexin
type 9
SNP = single nucleotide
polymorphism
TC = total cholesterol
VIC = valve interstitial cell
VLDL-C = very-low-density
lipoprotein cholesterol
wGRS = weighted genetic risk
score
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650HIGHLIGHTS
 Aortic stenosis was less prevalent in carriers of the PCSK9 R46L variant.
 Variation at the PCSK9 locus influences LDL-C levels, but not Lp(a).
 PCSK9 is produced and secreted by aortic valves.
 In vitro, PCSK9 inhibition might lower calcification in aortic valve cells.
 PCSK9 inhibition could represent a therapeutic strategy for aortic stenosis.SUMMARYCe
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régThe authors investigated whether PCSK9 inhibition could represent a therapeutic strategy in calcific aortic valve
stenosis (CAVS). A meta-analysis of 10 studies was performed to determine the impact of the PCSK9 R46L
variant on CAVS, and the authors found that CAVS was less prevalent in carriers of this variant (odds ratio: 0.80
[95% confidence interval: 0.70 to 0.91]; p ¼ 0.0011) compared with noncarriers. PCSK9 expression was higher
in the aortic valves of patients CAVS compared with control patients. In human valve interstitials cells sub-
mitted to a pro-osteogenic medium, PCSK9 levels increased and a PCSK9 neutralizing antibody significantly
reduced calcium accumulation. (J Am Coll Cardiol Basic Trans Science 2020;5:649–61) © 2020 The Authors.
Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).C alcific aortic valve stenosis (CAVS) isthe most common form of heartvalve disease, and its prevalence is
steadily rising in Western societies, affecting
almost 3% of the population older than 65
years of age (1). Identification of the risk fac-
tors for CAVS could facilitate the develop-
ment of novel and innovative treatment
strategies. To date, the only effective treat-
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651Proprotein convertase subtilisin/kexin type 9
(PCSK9) is an enzyme secreted by the liver that binds
to the LDL receptor (LDLR) and targets it for lyso-
somal degradation (7). Genetic association studies
have shown that natural variations at the PCSK9 locus
(present in 2% to 3% of the population) are associated
with lifelong exposure to low LDL-C levels, and car-
diovascular protection (8,9). PCSK9 inhibitors have
been shown to substantially lower LDL-C levels in
various populations and reduce the risk of adverse
cardiovascular outcomes in patients at high cardio-
vascular risk (10,11).
Lifelong low LDL-C levels has also been linked to
lower aortic valve calcium accumulation and protec-
tion against CAVS (12). Recently, investigators of the
Copenhagen General Population Study, the Copen-
hagen City Heart Study, and the Copenhagen
Ischemic Heart Disease Study observed that in-
dividuals carrying the R46L variant in PCSK9 are
characterized by lower levels of LDL-C, lipoprotein(a)
(Lp(a)), and a lower risk of CAVS (13). However, these
results have not been replicated, and it is still unclear
whether the cardiovascular benefits are due to
changes in LDL-C, Lp(a), or both. It also remains un-
clear whether PCSK9 is expressed in human aortic
valves and whether it contributes to valve interstitial
cell (VIC) calcification.
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whether blocking PCSK9 could mitigate the impact
of pro-osteogenic conditions on human VIC
calcification.
METHODS
GENETIC ASSOCIATION STUDY OF PCSK9 R46L
VARIANT AND CAVS. We investigated the associa-
tion between the R46L PCSK9 variant and CAVS in a
meta-analysis of 1 published (Copenhagen General
Population Study, Copenhagen City Heart Study, and
Copenhagen Ischemic Heart Disease Study, totaling
1,437 cases and 99,040 control patients [13]) and 9
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652control patients, the QUEBEC-CAVS study 1,009 cases
and 11,625 control patients, and 3 French cohorts
3,123 cases and 6,532 control patients). This meta-
analysis was performed after each study had tested
the impact of this variant on CAVS using logistic
regression adjusted for age and sex, and the first 10
ancestry-based principal components when available.
We performed a fixed-effect meta-analysis using the
inverse-variance weighted method as implemented in
the rmeta package (version 3.0) in R version 3.5.1
software (R Foundation for Statistical Computing,
Vienna, Austria). The design of each study and the
definition of CAVS is presented in the Supplemental
Appendix. All study protocols were approved by
local ethics committees, and all patients provided
informed consent. A summary of the definition of
CAVS in each cohort is described in
Supplemental Table 1.
GENETIC ASSOCIATION STUDIES IN THE
EPIC-NORFOLK STUDY. We selected independent (in
low linkage disequilibrium) single nucleotide poly-
morphisms (SNPs) (r2 < 0.10) at the PCSK9 locus
(within 100 Kb of the gene) associated with LDL-C
levels at a genome-wide level of significance in the
Global Lipids Genetics Consortium (GLGC) (14). This
approach yielded 11 SNPs independently associated
with LDL-C levels. Of these, 10 were successfully
genotyped in the EPIC-Norfolk study (described in
Supplemental Table 2). The design of the EPIC-
Norfolk prospective population study has been pub-
lished previously (15,16). We built a weighted genetic
risk score (wGRS) using these 10 SNPs weighted by
the effect of each SNP on LDL-C levels in the GLGC.
We then assessed the relationship between each of
the 10 SNPs individually and the wGRS with plasma
lipoprotein-lipid levels (total cholesterol [TC], LDL-C,
high-density lipoprotein cholesterol [HDL-C], very-
low-density lipoprotein cholesterol [VLDL-C], tri-
glycerides, apolipoprotein B [apoB], apolipoprotein
A-1 [apoA-I], and Lp[a]) in 9,692 participants of the
EPIC-Norfolk study using linear regression, adjusted
for age and sex. We considered a p value of 0.00625
(0.05 of 8 lipid traits) as statistically significant.
Because lipoprotein-lipid levels are not normally
distributed, the associations between the wGRS and
natural log-transformed lipoprotein-lipid levels were
assessed. We also constructed a wGRS scaled to a
1 mmol/l reduction in LDL-C levels. In the EPIC-
Norfolk study, serum levels of total cholesterol,
HDL-C, and triglycerides were measured in fresh
samples with the RA 1000 (Bayer Diagnostics,
Basingstoke, United Kingdom). LDL-C levels were
calculated using the Friedewald formula, and VLDL-C
levels were calculated as TC minus LDL-C minusHDL-C. Lp(a) and apoB levels were measured in a
subset of the cohort with available stored frozen
blood samples. Lp(a) levels were measured with an
immunoturbidimetric assay using polyclonal anti-
bodies directed against epitopes in apolipoprotein(a)
(Denka Seiken, Coventry, United Kingdom), as pre-
viously described (17). This assay has been shown to
be apolipoprotein(a) isoform-independent. Serum
levels of apoB were measured by rate immunone-
phelometry (Behring Nephelometer BNII, Marburg,
Germany) with calibration traceable to the Interna-
tional Federation of Clinical Chemistry pri-
mary standards.
GENETIC ASSOCIATION STUDIES IN THE UK
BIOBANK. The design of the UK Biobank has also
been previously published (18). The present analyses
were conducted under UK Biobank data application
number 25205. The associations between the wGRS
and prevalent CAVS in the UK Biobank were tested
using logistic regression adjusted for age, sex, and the
first 10 ancestry-based principal components using R
version 3.5.1 software.
HUMAN AORTIC VALVE COLLECTION. Patients
requiring aortic valve replacement due to CAVS were
prospectively enrolled in this study at Centro Car-
diologico Monzino IRCCS. Control valves were har-
vested from people deceased for noncardiovascular
causes, and the valves were provided by the Cardio-
vascular Tissue Bank at Centro Cardiologico Monzino.
Inclusion criteria for CAVS patients were elective
surgery, age more than 18 years, ejection fraction
>30%, and normal sinus rhythm. Exclusion criteria
were prior cardiac surgery, rheumatic heart disease,
endocarditis, active malignancy, chronic liver or
kidney diseases, calcium regulation disorders (hy-
perparathyroidism, hyperthyroidism, and hypothy-
roidism), and chronic or acute inflammatory states
(sepsis, autoimmune disease, and inflammatory
bowel disease). Aortic valve specimens were collected
from the operating room and processed within
30 min. The demographic and clinical characteristics
of enrolled patients are reported in Supplemental
Table 3. This study was approved by the IRCCS Cen-
tro Cardiologico Monzino Institutional Review Board
and by the IRCCS Istituto Europeo di Oncologia and
Centro Cardiologico Monzino Ethics Committee, and
informed consent was obtained from all
the participants.
HISTOLOGICAL EVALUATION OF PCSK9 EXPRESSION
AND AORTIC LEAFLET CALCIFICATION. Tissues were
washed 3 times in phosphate-buffered saline (PBS) 1
and were fixed in 4% formalin, dehydrated, included
in paraffin, and cut into 5- to 7-mm slides. Before
FIGURE 1 Association of the PCSK9 R46L Variant With CAVS
Association of the PCSK9 R46L variant with calcific aortic valve stenosis in a meta-analysis of 10 cohorts totaling 12,059 cases and 541,081 control subjects.
CAVS ¼ calcific aortic valve stenosis; CI ¼ confidence interval; EPIC ¼ European Prospective Investigation into Cancer and Nutrition; GERA ¼ Genetic Epidemiology
Research on Aging study; MDCS ¼ Malmo Diet and Cancer Study; OR ¼ odds ratio.
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653staining, slides were rehydrated. Von Kossa staining
was carried out with silver nitrate added on top of
each section and exposed to ultraviolet illumination
at room temperature for 20 min. Slides were washed
in deionized H2O and then incubated in sodium
thiosulfate solution 2 g/dl (Sigma-Aldrich, St. Louis,
Missouri) at room temperature for 5 min. Slides were
washed 3 times in deionized H2O and then incubated
for 10 s with hematoxylin. Slides were dehydrated,
mounted with EUKITT (O. Kindler/Orsatec, Bobingen,
Germany), and images were taken with AxioScope
(Carl Zeiss, Oberkochen, Germany). For PCSK9 stain-
ing, slides were incubated in antigen retrieval solu-
tion (Target Retrieval Solution Citrate [pH 6], Dako
Cytomation, Glostrup, Denmark) at 98C for 20 min
and then cooled at room temperature for 20 min.
Slides were treated with 3% H2O2 to block endoge-
nous peroxidases and then washed 3 times with 1
PBS with 0.1% Triton (PBST). Blocking solution (PBST
and 5% bovine serum albumin) was added and kept
for 45 min at room temperature. Slides were incu-
bated with primary mouse monoclonal anti-PCSK9
(Abcam, Cambridge, United Kingdom) at 4C over-
night. Slides were washed 3 times with PBST and
incubated with biotinylated anti-mouse secondary
antibody (Vector Laboratories, Burlingame, Califor-
nia) for 60 min at room temperature. Slides were
washed 3 times and ABC complex (ABC kit, Vector
Laboratories) was added and incubated for 30 min at
room temperature. Slides were washed 3 times, and
ImmPACT DAB Peroxidase (HRP) Substrate (Vector
Laboratories) was added and let react for 25 s. Slides
were immediately rinsed in distilled H2O and thenincubated for 10 s with hematoxylin. Slides were
dehydrated, mounted with EUKITT (O. Kindler/Orsa-
tec), and images were taken with AxioScope (Carl
Zeiss). The quantification of PCSK9 immunohisto-
chemistry has been performed implementing the
ImageJ v1.50i software (NIH, Bethesda, Maryland)
with the plugin IHC Tool box. The automated color
detection, which allows the generation of deconvo-
luted images, has been performed with the default
model H-DAB for brown color detection. The inte-
grate pixel density has been calculated on binary
panoramic images and normalized with the total area
of the section (pixel2).
PCSK9 MEASUREMENTS IN EXPLANTED AORTIC
VALVES AND VIC MEDIUM. Whole-protein extracts
were obtained by pulverizing frozen aortic valve leaf-
lets. The powder was suspend in 1 RIPA buffer with
the addition of protease inhibitors (Sigma-Aldrich) and
assayed as follows. VIC supernatant culture medium
was collected at the end of the treatments and assayed
as follows. The PCSK9 quantification was carried
out with an enzyme-linked immunosorbent assay
(R&D Systems, Minneapolis, Minnesota) following
the manufacturer’s instructions. The intraplate
and the interplate percent coefficients of variation for
PCSK9 protein measurements were 3.2  0.3% and
8.4  0.9%, respectively.
AORTIC VALVE INTERSTITIAL CELL ISOLATION.
Isolation of aortic VICs was performed using a
modified method described by Poggio et al. (19).
Briefly, aortic leaflets were placed in 2 mg/ml type II
collagenase (Worthington Biochemical Corporation,
TABLE 1 Association of 10 Independent SNPs at the PCSK9 Locus and of a wGRS With Natural Log-Transformed Lipoprotein-Lipid Levels in 9,692 Participants of
the EPIC-Norfolk Study
TC p Value* LDL-C p Value* HDL-C p Value* VLDL-C p Value*
rs585131 1.2 (0.75) 0.092 1.3 (0.69) 0.046 0.017 (0.0068) 0.013 0.11 (0.28) 0.738
rs2483205 0.15 (0.60) 0.764 0.52 (0.55) 0.352 0.00013 (0.0054) 0.971 0.37 (0.22) 0.089
rs2479394 0.41 (0.69) 0.541 0.79 (0.63) 0.201 0.012 (0.0062) 0.088 0.37 (0.25) 0.173
rs10493176 2.2 (1.1) 0.037 2.0 (0.97) 0.043 0.00082 (0.0096) 0.958 0.18 (0.39) 0.520
rs11206510 1.7 (0.74) 0.011 1.2 (0.68) 0.029 0.0099 (0.0067) 0.101 0.46 (0.27) 0.053
rs2479409 1.6 (0.64) 0.010 1.7 (0.58) 0.003 0.0030 (0.0057) 0.590 0.12 (0.23) 0.557
rs12067569 0.33 (1.8) 0.866 1.9 (1.7) 0.189 0.016 (0.017) 0.363 1.6 (0.68) 0.021
rs10888896 1.8 (0.69) 0.0057 2.0 (0.63) <0.001 0.0046 (0.0062) 0.489 0.18 (0.25) 0.459
rs11591147 19.8 (2.5) <0.001 18.2 (2.3) <0.001 0.030 (0.023) 0.183 1.6 (0.92) 0.035
rs7552841 2.8 (0.62) <0.001 2.5 (0.57) <0.001 0.0037 (0.0056) 0.514 0.32 (0.23) 0.146
wGRS 16.9 (2.4) <0.001 16.5 (2.2) <0.001 0.027 (0.022) 0.190 0.41 (0.90) 0.463
TABLE 1 Continued
TG p Value* apoB p Value* apoA-I p Value* Lp(a) p Value*
rs585131 3.8 (1.3) 0.003 0.0047 (0.0043) 0.248 0.0051 (0.0055) 0.269 0.27 (0.43) 0.877
rs2483205 1.9 (1.0) 0.064 0.0010 (0.0034) 0.949 0.0046 (0.0043) 0.333 0.086 (0.34) 0.901
rs2479394 0.32 (1.2) 0.906 0.0088 (0.0039) 0.033 0.0077 (0.0050) 0.135 0.42 (0.39) 0.909
rs10493176 1.2 (1.8) 0.579 0.0060 (0.0060) 0.540 0.014 (0.0077) 0.042 0.72 (0.60) 0.410
rs11206510 0.65 (1.3) 0.660 0.0051 (0.0042) 0.213 0.0016 (0.0054) 0.805 0.19 (0.42) 0.952
rs2479409 0.024 (1.1) 0.613 0.0024 (0.0036) 0.698 0.011 (0.0046) 0.014 0.17 (0.36) 0.669
rs12067569 4.4 (3.1) 0.052 0.0057 (0.010) 0.767 0.013 (0.013) 0.372 0.85 (1.0) 0.381
rs10888896 1.9 (1.2) 0.503 0.0039 (0.0039) 0.413 1.9e05 (0.0050) 0.711 0.44 (0.39) 0.600
rs11591147 2.6 (4.3) 0.602 0.068 (0.014) <0.001 0.0042 (0.018) 0.888 0.33 (1.4) 0.585
rs7552841 0.81 (1.1) 0.476 0.0093 (0.0035) 0.022 0.0015 (0.0045) 0.837 0.23 (0.35) 0.742
wGRS 2.9 (4.1) 0.369 0.056 (0.014) <0.001 0.018 (0.018) 0.202 1.7 (1.4) 0.435
Values are beta (SE). All associations were adjusted for age and sex. *Level of statistical significance was set as 0.00625 (0.05/8 lipid traits) on log-transformed values.
apoA-I ¼ apolipoprotein A-I; apoB ¼ apolipoprotein B; Lp(a) ¼ lipoprotein(a); HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol; SNP ¼ single nucleotide
polymorphisms; TC ¼ total cholesterol; TG ¼ triglycerides; VLDL-C ¼ very-low-density lipoprotein cholesterol.
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654Lakewood, New Jersey) in advanced Dulbecco’s
modified Eagle’s medium (Ad DMEM) containing
10% fetal bovine serum, L-glutamine 2 mmol/l, and
1% penicillin/streptomycin solution and incubated at
37C for 20 min. The loosened endothelial layer was
removed, and tissues were finely minced and
dissociated in type II collagenase (1 mg/ml) for 4 h
at 37C. The resulting VICs were seeded in tissue
culture plates in Ad DMEM (Thermo Fisher Scienti-
fic, Waltham, Massachusetts) medium and main-
tained at 37C with 5% CO2. All the experiments
were performed on cultured cells between their
second and fifth passages in Ad DMEM containing
10% fetal bovine serum, 1% penicillin, 1% strepto-
mycin solution, and 1% L-glutamine
(normal medium).
IMPACT OF OSTEOGENIC STIMULI ON PCSK9
EXPRESSION IN VICs. To evaluate PCSK9 expression
under osteogenic stimuli, VICs were treated with
normal medium and osteogenic medium
(þ10 mmol/l b-glycerophosphate and þ50 mg/ml
ascorbic acid) with or without a neutralizing anti-
body anti-PCSK9 (NAb anti-PCSK9, 0.8 ng/ml, BPSBioscience, San Diego, California) or immunoglob-
ulin G1 as control (IgG1, 0.8 ng/ml, Novus Bi-
ologicals, Centennial, Colorado) for 7 days. Total
cell RNA was isolated using a Total RNA Purification
kit (Norgen Biotek Corp., Thorold, Ontario, Canada),
following the manufacturer’s protocol. RNA quanti-
fication was determined with a spectrophotometer
(ND-1000, NanoDrop, EuroClone). Reverse tran-
scription was performed with the TaqMan Reverse
Transcription Reagent (Applied Biosystems, Foster
City, California) following the manufacturer’s in-
structions. Quantitative real-time polymerase chain
reaction was executed by the use of the SYBR
Green PCR MasterMix (Applied Biosystems). All re-
actions were performed in a MicroAmp Fast 96-Well
Reaction Plate (Applied Biosystems). The relative
quantities of specific mRNA were obtained with the
use of the comparative Ct method and were
normalized to glyceraldehyde 3-phosphate dehy-
drogenase gene (GAPDH). Calcium quantification
was performed by calcium colorimetric assay (Bio-
Vision, Milpitas, California) following the manufac-
turer’s instructions.
FIGURE 2 Impact of Individual SNPs and a wGRS on CAVS
Impact of individual single nucleotide polymorphisms (SNPs) (A) and of a weighted genetic risk score of single nucleotide polymorphisms at
the PCSK9 locus associated with low-density cholesterol (LDL-C) levels only (B) on calcific aortic valve stenosis in the UK Biobank.
wGRS ¼ weighted genetic risk score; other abbreviations as in Figure 1.
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655STATISTICAL ANALYSIS. For continuous data, nor-
mally distributed values were compared between
groups with Student’s t-test, and the results were
expressed as mean  SD; not normally distributed
values were compared between groups with Mann-
Whitney test, and the results were expressed as
median (interquartile range [IQR]); whereas
categorical values were compared with Pearson’s
chi-square test, and the results were expressed as
mean and percentage. The measure of the linear
correlation between in vitro PCSK9 secretion and
calcium deposition was performed with the Pearson
correlation coefficient (rp). Each value has been
previously “mean-centered.” Data were analyzedwith GraphPad Prism v7.00 software (GraphPad
Prism, San Diego, California), and a value of p < 0.05
was considered statistically significant.
RESULTS
META-ANALYSIS OF THE ASSOCIATION BETWEEN
THE PCSK9 R46L VARIANT AND CAVS. Figure 1 pre-
sents the association between the PCSK9 R46L
variant and CAVS in 1 published and 9 previously
unpublished studies totaling 12,059 CAVS cases and
541,081 control patients. Carriers of the R46L variant
had lower odds of CAVS compared with noncarriers
(odds ratio: 0.80 [95% confidence interval: 0.70 to
FIGURE 3 PCSK9 Is Highly Abundant in Calcified Leaflets
(A) Representative explanted aortic valve leaflet with normal structure (control valve) and (B) representative calcified aortic valve leaflet (stenotic valve), both stained
with Von Kossa to visualize calcium deposits (upper panels) and with anti-PCSK9 antibody (lower panels). PCSK9 immunohistochemical (IHC) staining is presented as
3,30-diaminobenzidine (DAB) and hematoxylin (H) counter staining (DAB þ H) and as deconvoluted image visualizing only the DAB staining. Panoramic images were
taken with a 10 magnification. Black boxes indicate the higher magnification areas. (C and D) High magnification areas of aortic valve leaflets (20 left and 40
right). Arrows indicate representative PCSK9 expression in close proximity to cell nuclei. (E) Box and whisker plots represent DAB quantification by ImageJ with IHC
Tool box plugin on normal (control; n ¼ 6) and calcified (stenotic; n ¼ 6) leaflets. (F) Box and whisker plots represent PCSK9 levels measured by enzyme-linked
immunosorbent assay on control (n ¼ 6) and stenotic (n ¼ 6) whole tissue extracts.
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FIGURE 4 PCSK9 Expression and Secretion Is Induced by Osteogenic Milieu in Valve Interstitial Cells
(A) Box and whisker plots represent PCSK9 transcript levels in valve interstitial cells (VIC) cultured for 7 days in normal or osteogenic media (n ¼ 6). RNA levels were
normalized to GAPDH expression. (B) Box and whisker plots represent secreted PCSK9 levels from VICs cultured for 7 days in normal or osteogenic media (n ¼ 4).
PCSK9 levels were normalized to total protein content. (C) Mean-centered correlation between secreted PCSK9 and calcium levels in VICs. The linear correlation
between the 2 variables was performed with the Pearson correlation coefficient. (D) Bar graph shows the calcification potential, after 7 days, in normal and osteogenic
media (n ¼ 3) of VICs treated with a neutralizing antibody anti-PCSK9 (NAb anti-PCSK9) or immunoglobulin G1 as control (IgG1).
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6570.91]; p < 0.001). A funnel plot of the resulting meta-
analysis is presented in Supplemental Figure 1. The
p value for heterogeneity was 0.418.
PCSK9 VARIANTS, LIPOPROTEIN-LIPID LEVELS,
AND CAVS. The association between the 10 PCSK9
SNPs as well as the wGRS and natural log-transformedlipoprotein-lipid levels in 9,692 participants of the
EPIC-Norfolk study are presented in Table 1. The
wGRS was significantly associated with TC, LDL-C,
and apoB (all p < 0.001), but not with VLDL-C
(although the R46L variant [rs11591147] was associ-
ated with lower VLDL-C levels), HDL-C, triglycerides,
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658apoA-I, or Lp(a). In the UK Biobank, the wGRS asso-
ciated with lower LDL-C was associated with lower
odds of CAVS (odds ratio: 0.55 [95% confidence in-
terval: 0.39 to 0.77]; p < 0.001) per 1 mmol/l reduction
in LDL-C (Figure 2).
PCSK9 EXPRESSION AND CAVS. Immunohisto-
chemical analysis identified PCSK9 in both calcified
and noncalcified leaflets. However, PCSK9 was highly
abundant in calcified ones (fold change þ3.5
[IQR: þ1.7 to þ20.9]; p ¼ 0.009) compared with non-
calcified leaflets (Figure 3A, 3B, and 3E and
Supplemental Figures 2 and 3). In healthy aortic
valves, PCSK9 is detectable only in close proximity to
cell nuclei, whereas in stenotic ones, PCSK9 is present
also within the extracellular matrix (Figures 3C and 3D
and Supplemental Figure 2). Enzyme-linked immu-
nosorbent assay confirmed that PCSK9 is overex-
pressed in calcified leaflets compared with healthy
ones (315.8 [IQR: 216.4 to 547.9] vs. 2.3 [IQR: 0.0 to
88.1] pg of PCSK9/mg of total proteins, respectively;
p ¼ 0.002) (Figure 3F).
PCSK9 SECRETION AND VIC CALCIFICATION. We
sought to determine whether CAVS VICs could ex-
press PCSK9 under classic osteogenic stimulus. We
treated human isolated VICs with osteogenic medium
and then evaluated PCSK9 mRNA and secreted PCSK9
protein levels. PCSK9 transcript expression was
induced by osteogenic medium treatment (log2 fold
change ¼ þ1.0 [IQR: þ0.66 to þ1.4]; p ¼ 0.005)
compared with VICs in normal medium (Figure 4A).
As expected, osteogenic medium induced VIC calci-
fication compared with normal medium (472.2 [IQR:
316.4 to 701.1] ng vs. 20.7 [IQR: 15.8 to 28.6] ng of
calcium/mg of total proteins, respectively; p < 0.0001)
(Supplemental Figure 4). In culture, VICs were able to
secrete a detectable amount of PCSK9 into the me-
dium. In particular, VICs treated with osteogenic
medium secreted significantly higher PCSK9 levels
compared with VICs in normal one (14.6 [IQR: 11.0 to
21.6] vs. 8.9 [IQR: 5.8 to 13.4] pg of PCSK9/mg of total
proteins, respectively; p < 0.001) (Figure 4B). We also
found a significant and positive correlation (Pearson’s
correlation coefficient rp ¼ 0.91; p < 0.0001) between
the extent of calcification and the amount of secreted
PCSK9 (Figure 4C). Finally, inhibition of extracellular
PCSK9 was able to significantly reduce the calcium
deposition both in normal medium (6.3%
[IQR: 6.8% to 0.4%]; p ¼ 0.02) and in osteogenic
medium (56.5% [IQR: 63.3% to 40.0%];
p < 0.0001) compared with their respective control
medium (Figure 4D).DISCUSSION
Previous genetic association studies observed that
carriers of genetic variants in PCSK9 associated with
low LDL-C levels are at lower risk of a broad range of
atherosclerotic cardiovascular diseases (20). In this
study, we confirmed that variants in PCSK9 associ-
ated with lower LDL-C levels are also associated with
a lower risk of CAVS, and for the first time to our
knowledge, we demonstrated that PCSK9 is present in
human aortic valves. Investigating the potential pa-
rameters of the lipoprotein-lipid profile that might
explain the benefits of carrying these variants, we
found LDL-C, but not Lp(a), levels to be a key factor
that may explain the benefits of carrying PCSK9 var-
iants for CAVS prevention. The potential benefits of
targeting PCSK9 for CAVS prevention were also sup-
ported by our in vitro experimental approach,
showing that treating VICs with a neutralizing PCSK9
antibody reduced calcium accumulation in VICs un-
der pro-osteogenic stimuli.
In a previous report of 2,373 individuals included
in a nested case-control design of the EPIC-Norfolk
study, we have shown that carriers of the PCSK9
R46L variant had lower levels of nuclear magnetic
resonance spectroscopy-measured VLDL and LDL
particle concentrations and lower Lp(a) (21). In
another study, Sliz et al. (22) reported no impact of
this variant on VLDL lipid measures. In our study,
we found a significant association between PCSK9
variants and CAVS in the UK Biobank. However,
given the relatively small number of CAVS cases in
the UK Biobank (1,350), these results are not
definitive, and additional studies are needed to
confirm these findings and to determine whether
the impact of reduced PCSK9 function is indepen-
dent of the presence of concomitant CAD because
approximately one-half of the patients with CAVS
also have CAD. Our results confirm those of the
Copenhagen cohorts (13) and extend our previous
observations that Pcsk9/ mice are less likely to
develop aortic valve calcification than wild-type
mice (23). Results of our previous study, confirmed
by the present one, also suggest that there is a
significant correlation between the amount of
PCSK9 produced by VICs and the extent of VIC
calcification (23). Our results are also in line with a
report from the CHARGE (Cohorts for Heart and
Aging Research in Genomic Epidemiology) con-
sortium and the MDCS study (Malmo Diet and
Cancer Study) that has shown that a GRS associated
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 5 , N O . 7 , 2 0 2 0 Perrot et al.
J U L Y 2 0 2 0 : 6 4 9 – 6 1 PCSK9 and Calcific Aortic Valve Stenosis
659with lifelong LDL-C reduction is associated with
lower aortic valve calcium accumulation and lower
CAVS incidence (12).
STUDY LIMITATIONS. In the current study, we
included additional participants and PCSK9 variants,
and found no association between SNPs in PCSK9 and
VLDL-C or Lp(a). Although our study population was
not as large, our results for Lp(a) are in contrast with
those of the Copenhagen investigators who have
shown that carriers of the R46L variant (n ¼ 1,293)
have approximately 10% lower Lp(a) levels compared
with noncarriers (n ¼ 48,324). Consequently, the
impact of PCSK9 variants on Lp(a) is at best modest.
Also in support of this premise, results of the
FOURIER (Further Cardiovascular Outcomes
Research With PCSK9 Inhibition in Subjects With
Elevated Risk) trial have shown that PCSK9 inhibition
with evolocumab provides modest (16%) reduction in
Lp(a) levels in patients with high Lp(a) levels (24),
suggesting that PCSK9 inhibitors may not exert their
cardiovascular benefits through Lp(a) reduction but
rather via reductions in other apoB-containing lipo-
protein particles such as LDL. These findings are also
supported by the recently published ANITSCHKOW
(Effects of Proprotein Convertase Subtilisin/Kexin
Type 9 [PCSK9] Inhibition on Arterial Wall Inflam-
mation in Patients With Elevated Lipoprotein(a)
[Lp(a)]) trial that concluded that PCSK9 inhibition
with evolocumab was associated with modest re-
ductions in Lp(a) and did not influence arterial wall
inflammation assessed by 18F-fluoro-deoxyglucose
positron-emission tomography/computed tomogra-
phy in patients with hyperlipoproteinemia(a) (25).
Because circulating PCSK9 levels were not measured,
we could not determine whether the benefits of car-
rying PCSK9 variants go beyond reductions in apoB
levels and could be due to lower plasma PCSK9
levels. Nevertheless, our results are in accordance
with 2 other studies from our group showing that
circulating PCSK9 levels are associated with bio-
prosthetic aortic valve degeneration (26,27). Our
ex vivo data confirmed that PCSK9 is more abundant
in the explanted aortic valve from patients with CAVS
compared with control patients. However, evaluating
the demographical and clinical variables between
control and CAVS patients, we found that age and
dyslipidemia significantly differed, being possible
confounders. However, the used specimens were 6
per group, and regression analyses adjusted for ageand/or dyslipidemia need to be interpreted with
caution. Nevertheless, our in vitro experiments pro-
vided evidence that VIC are indeed able to produce
and to secrete PCSK9. The proteins secreted by VIC
are entrapped within the extracellular matrix and do
not reach the blood stream. However, at the present
time, we are not able to differentiate between the
PCSK9 infiltrate from the blood stream and the PCSK9
locally produced by the VICs. Indeed, in vitro, we
found that VICs submitted to a procalcifying milieu
had an increase in PCSK9 levels, and we showed that
a direct block of extracellular VIC-released PCSK9
was able to significantly reduce calcium accumula-
tion. We believe that these results are important to
generate further studies focused on the molecular
mechanisms by which PCSK9 modulates VIC calcium
accumulation and thus aortic valve detri-
mental processes.
CONCLUSIONS
We performed a large genetic association study as
well as a series of experiments showing that variation
in PCSK9 is linked with low cholesterol levels and
protection against CAVS and that PCSK9 expression
was higher in explanted aortic valves from patients
with versus without CAVS. In human VICs, PCSK9
expression and secretion were induced by an expo-
sure to a pro-osteogenic milieu and a PCSK9
neutralizing antibody reduced VIC calcium levels by
more than 50%, thereby providing experimental
support to our genetic findings.
Although our results highlight the potential role of
PCSK9 in the etiology of CAVS, the ultimate proof of
causality and clinical benefit would be a clinical trial
showing that PCSK9 inhibition is linked with a reduc-
tion in valvular outcomes. However, to our knowl-
edge, no such trials are currently planned. An ongoing
trial is currently testing the hypothesis that PCSK9
inhibition will reduce aortic valve macrocalcification
(measured by computed tomography) and micro-
calcification (measured by 18F-NaF positron-emission
tomography/computed tomography) in patients with
mild-to-moderate CAVS (PCSK9 Inhibitors in the Pro-
gression of Aortic Stenosis; NCT03051360). Interest-
ingly, an exploratory analysis of the FOURIER trial
recently revealed that PCSK9 inhibition with evolo-
cumab could decrease CAVS incidence in patients with
cardiovascular disease (28).
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In
the absence of a pharmacological treatment delay-
ing CAVS progression and outcomes, PCSK9 inhibi-
tion could provide benefit to patients with CAVS
and our results provide a rationale for a large clin-
ical randomized trial to investigate the effect of
PCSK9 inhibition in patients with CAVS.
TRANSLATIONAL OUTLOOK: Our results high-
light the potential role of PCSK9 in the etiology of
CAVS and support the notion that targeting apoB-
containing lipoprotein particles such as LDL is key for
optimal CAD risk reduction and potentially CAVS.
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